Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS Pathog ; 12(11): e1005983, 2016 Nov.
Article in English | MEDLINE | ID: mdl-27855210

ABSTRACT

HIV-1 entry can be inhibited by soluble peptides from the gp41 heptad repeat-2 (HR2) domain that interfere with formation of the 6-helix bundle during fusion. Inhibition has also been seen when these peptides are conjugated to anchoring molecules and over-expressed on the cell surface. We hypothesized that potent anti-HIV activity could be achieved if a 34 amino acid peptide from HR2 (C34) were brought to the site of virus-cell interactions by conjugation to the amino termini of HIV-1 coreceptors CCR5 or CXCR4. C34-conjugated coreceptors were expressed on the surface of T cell lines and primary CD4 T cells, retained the ability to mediate chemotaxis in response to cognate chemokines, and were highly resistant to HIV-1 utilization for entry. Notably, C34-conjugated CCR5 and CXCR4 each exhibited potent and broad inhibition of HIV-1 isolates from diverse clades irrespective of tropism (i.e., each could inhibit R5, X4 and dual-tropic isolates). This inhibition was highly specific and dependent on positioning of the peptide, as HIV-1 infection was poorly inhibited when C34 was conjugated to the amino terminus of CD4. C34-conjugated coreceptors could also inhibit HIV-1 isolates that were resistant to the soluble HR2 peptide inhibitor, enfuvirtide. When introduced into primary cells, CD4 T cells expressing C34-conjugated coreceptors exhibited physiologic responses to T cell activation while inhibiting diverse HIV-1 isolates, and cells containing C34-conjugated CXCR4 expanded during HIV-1 infection in vitro and in a humanized mouse model. Notably, the C34-conjugated peptide exerted greater HIV-1 inhibition when conjugated to CXCR4 than to CCR5. Thus, antiviral effects of HR2 peptides can be specifically directed to the site of viral entry where they provide potent and broad inhibition of HIV-1. This approach to engineer HIV-1 resistance in functional CD4 T cells may provide a novel cell-based therapeutic for controlling HIV infection in humans.


Subject(s)
CD4-Positive T-Lymphocytes/virology , HIV Envelope Protein gp41/metabolism , HIV Infections/metabolism , HIV-1/metabolism , Peptide Fragments/metabolism , Receptors, CXCR4/metabolism , Virus Internalization , Animals , CD4-Positive T-Lymphocytes/metabolism , Flow Cytometry , HEK293 Cells , Humans , Mice , Mice, Inbred NOD
2.
Genome Res ; 22(7): 1316-26, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22434427

ABSTRACT

Zinc-finger nucleases (ZFNs) drive highly efficient genome editing by generating a site-specific DNA double-strand break (DSB) at a predetermined site in the genome. Subsequent repair of this break via the nonhomologous end-joining (NHEJ) or homology-directed repair (HDR) pathways results in targeted gene disruption or gene addition, respectively. Here, we report that ZFNs can be engineered to induce a site-specific DNA single-strand break (SSB) or nick. Using the CCR5-specific ZFNs as a model system, we show that introduction of a nick at this target site stimulates gene addition using a homologous donor template but fails to induce significant levels of the small insertions and deletions (indels) characteristic of repair via NHEJ. Gene addition by these CCR5-targeted zinc finger nickases (ZFNickases) occurs in both transformed and primary human cells at efficiencies of up to ∼1%-8%. Interestingly, ZFNickases targeting the AAVS1 "safe harbor" locus revealed similar in vitro nicking activity, a marked reduction of indels characteristic of NHEJ, but stimulated far lower levels of gene addition-suggesting that other, yet to be identified mediators of nick-induced gene targeting exist. Introduction of site-specific nicks at distinct endogenous loci provide an important tool for the study of DNA repair. Moreover, the potential for a SSB to direct repair pathway choice (i.e., HDR but not NHEJ) may prove advantageous for certain therapeutic applications such as the targeted correction of human disease-causing mutations.


Subject(s)
Deoxyribonucleases, Type II Site-Specific/metabolism , Gene Targeting/methods , Genome, Human , Recombinant Fusion Proteins/metabolism , Zinc Fingers , Amino Acid Sequence , Catalytic Domain , Cell Line, Transformed , Cell Line, Tumor , Cloning, Molecular , DNA Breaks, Double-Stranded , DNA Breaks, Single-Stranded , DNA End-Joining Repair , Deoxyribonucleases, Type II Site-Specific/genetics , Fibroblasts/cytology , Fibroblasts/metabolism , Genetic Vectors , Histones/metabolism , Humans , INDEL Mutation , Molecular Sequence Data , Protein Engineering/methods , Receptors, CCR5/genetics , Recombinant Fusion Proteins/genetics , Saccharomyces cerevisiae/genetics , Saccharomyces cerevisiae/metabolism , Transformation, Genetic
3.
Mol Ther ; 20(4): 849-59, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22273578

ABSTRACT

HIV-1-infected individuals can harbor viral isolates that can use CCR5, as well as CXCR4, for viral entry. To genetically engineer HIV-1 resistance in CD4(+) T cells, we assessed whether transient, adenovirus delivered zinc-finger nuclease (ZFN) disruption of genomic cxcr4 or stable lentiviral expression of short hairpin RNAs (shRNAs) targeting CXCR4 mRNAs provides durable resistance to HIV-1 challenge. ZFN-modification of cxcr4 in CD4(+) T cells was found to be superior to cell integrated lentivirus-expressing CXCR4 targeting shRNAs when CD4(+) T cells were challenged with HIV-1s that utilizes CXCR4 for entry. Cxcr4 disruption in CD4(+) T cells was found to be stable, conferred resistance, and provided for continued cell enrichment during HIV-1 infection in tissue culture and, in vivo, in peripheral blood mononuclear cell transplanted NSG mice. Moreover, HIV-1-infected mice with engrafted cxcr4 ZFN-modified CD4(+) T cells demonstrated lower viral levels in contrast to mice engrafted with unmodified CD4(+) T cells. These findings provide evidence that ZFN-mediated disruption of cxcr4 provides a selective advantage to CD4(+) T cells during HIV-1 infection.


Subject(s)
CD4-Positive T-Lymphocytes/metabolism , Endonucleases/metabolism , HIV-1/immunology , RNA, Small Interfering/genetics , Receptors, CXCR4/genetics , Adenoviridae/genetics , Animals , CD4-Positive T-Lymphocytes/immunology , Cells, Cultured , Endonucleases/genetics , Humans , Mice , Zinc Fingers/genetics
4.
Nat Biotechnol ; 29(2): 143-8, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21179091

ABSTRACT

Nucleases that cleave unique genomic sequences in living cells can be used for targeted gene editing and mutagenesis. Here we develop a strategy for generating such reagents based on transcription activator-like effector (TALE) proteins from Xanthomonas. We identify TALE truncation variants that efficiently cleave DNA when linked to the catalytic domain of FokI and use these nucleases to generate discrete edits or small deletions within endogenous human NTF3 and CCR5 genes at efficiencies of up to 25%. We further show that designed TALEs can regulate endogenous mammalian genes. These studies demonstrate the effective application of designed TALE transcription factors and nucleases for the targeted regulation and modification of endogenous genes.


Subject(s)
Combinatorial Chemistry Techniques/methods , Genetic Engineering , Mutagenesis, Site-Directed/methods , Transcription Factors/genetics , Transcription Factors/metabolism , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Base Sequence , Binding Sites , DNA/genetics , DNA/metabolism , Deoxyribonucleases, Type II Site-Specific/genetics , Deoxyribonucleases, Type II Site-Specific/metabolism , Genome , Humans , K562 Cells , Molecular Sequence Data , Receptors, CCR5/genetics , Vascular Endothelial Growth Factor A/genetics , Xanthomonas
SELECTION OF CITATIONS
SEARCH DETAIL
...